Pulmonary Arterial Hypertension (PAH) Infused/Inhaled Enrollment Form



Fax Referral To: 1-877-232-5455

Phone: 1-800-896-1464 Address: 500 Ala Moana Blvd., Ste 1-A Honolulu, HI 96813

	Six Simple Steps to Submitting a Referral
PATIENT INFORMATION (Complete	
Patient Name:	
	City, State, ZIP Code:
Gender: Male Female	
-	to primary # provided below)
	Alternate Phone:
	lame (Last, First):
Relationship to minor:	
Email:	Last Four of SSN: Primary Language:
2 PRESCRIBER INFORMATION	
Prescriber's Name:	State License #:
NPI #: DEA #:	Group or Hospital:
Address:	City, State, ZIP Code:
Phone: Fax	City, State, ZIP Code: Contact's Phone:
	se fax copy of prescription and insurance cards with this form, if available (front and back)
4 DIAGNOSIS AND CLINICAL INFO	
Needs by Date:	Ship to: Patient Office Other:
<u>Diagnosis (ICD-10):</u>	
Date of Diagnosis:	
☐ I27.0 Primary Pulmonary Hypertens	sion I27.20 Pulmonary Hypertension, Unspecified
☐ I27.21 Secondary Pulmonary Arteria	al Hypertension 🔲 I27.24 Chronic Thromboemolic Pulmonary Hypertension
☐ I27.83 Eisenmenger's Syndrome	☐ I27.89 Other Specified Pulmonary Disease
Other Code:	Description
Patient Clinical Information:	
	ınctional Classification: 🔲 I 🔲 II 📗 III 📗 IV
6 Minute Walk Distance:	
	for pulmonary hypertension? Yes No
If Yes, name of drug(s):	
Weight:lb/kg Height:	
	cal Right Heart Catheterization Calcium Channel Blocker Statement Echocardiogram
Nursing: Not Needed Pre-hospit	al/Pre-home Teaching 🔲 In-hospital Teaching 🔲 Nursing Follow-up
Start of care date: Nur	mber of visits:
Prostacyclin Referral Information:	
Check the boxes below to designate	which items are included in this fax:
PAH diagnosis and ICD-10 code (design	
Is Medicare Part B the primary insurance	
Clinical documentation	
Current H&P (within 6 months); Date	re of H&P:
_	Check below if included in the RHC report
	iastolic) > 25 mmHg at rest or > 30 mmHg with exertion
Cardiac Output	Cardiac Index
Pulmonary Vascular Resistance	Pulmonary Capillary Wedge Pressure (or LVEDP) < 15 mmHg
Echocardiogram	
Calcium Channel Blocker statemer	t with supporting documentation
	states will require documentation that the PAH is out-of-proportion with the secondary disease: Left
_	ung disease, sarcoidosis and other co-morbidities, except for the ones listed in WHO Group I
category	
	75 445044 00/00/00

Pulmonary Arterial Hypertension (PAH) Infused/Inhaled Enrollment Form

Tyvaso, Ventavis, Flolan, Epoprostenol (Generic Flolan), Remodulin

			Prescriber Information	
			Patient DOB:	
Prescriber Name:			Prescriber Phone:	·
5 PRESCRIPTION				
INHALED PRODUC				
MEDICATION	STRENGTH			QUANTITY/REFILLS
Tyvaso (treprostinil) Inhalation Solution	☐ Tyvaso Inhalation System Starter Kit ☐ Tyvaso Refill Kit	3-4 breaths at 1-2 we	ths (18 mcg) four times daily. Increase by eek intervals, if tolerated, until the target 4 mcg) four times daily.	Quantity: 28-day supply Refills:
Ventavis (iloprost) Inhalation Solution	NA	CVS Specialty as you	rentavis enrollment form and indicate ur preferred pharmacy provider. The sed at www.4ventavis.com or by 546.	Quantity: 0 Refills: 0
INFUSED THERAPII MEDICATION	STRENGTH	D	OSE & DIRECTIONS	QUANTITY/REFILLS
Flolan (epoprostenol) for injection	O.5 mg vial 1.5 mg vial Sterile diluent for Flolan pH 12 sterile diluent for Flolan	 □ IV infusion continuous over 24 hours Initial dose: ng/kg/min. Titrate by ng/kg/min every days until goal of ng/kg/min achieved. Discharge dose: ng/kg/min Concentration: ng/mL Pump: 2 CADD-Legacy Pumps CVC Care: Dressing change every days. □ Per IV standard of care 		Quantity: One-month supply of drug and supplies. Dosing weight: kg/lb Refills:
Epoprostenol (Generic Flolan)	☐ 0.5 mg vial ☐ 1.5 mg vial ☐ Epoprostenol diluent	□ IV infusion continuous over 24 hours Initial dose: ng/kg/min. Titrate by ng/kg/min every days until goal of ng/kg/min achieved. Discharge dose: ng/kg/min Concentration: ng/mL Pump: 2 CADD-Legacy Pumps CVC Care: □ Dressing change every days. □ Per IV standard of care		Quantity: One-month supply of drug and supplies. Dosing weight: kg/lb Refills:
Remodulin (treprostinil) for injection	☐ 1 mg/mL, 20 mL vial ☐ 2.5 mg/mL, 20 mL vial ☐ 5 mg/mL, 20 mL vial ☐ 10 mg/mL, 20 mL vial	SC continuous over 24 hours Initial dose: ng/kg/min. Titrate by ng/kg/min every days until goal of ng/kg/min achieved. Change infusion site every days. Palliative med PRN Pumps: 2 CADD-MS3 pumps IV infusion continuous over 24 hours Initial dose: ng/kg/min. Titrate by ng/kg/min every days until goal of ng/kg/min achieved. Diluent: Check one (Sterile diluent for Remodulin will be used if no box is checked) 0.9% NaCl for injection		
Patient is interested in pati		SIGNATURE NOT ALLOWED	Ancillary supplies and kits provided	
6	PRESCRIBER SIGNATU	IKE REQUIRED (ST	TAMP SIGNATURE NOT ALLOWED	<u>)</u>
	Brand Medically Necessary / Do Not Sub	ostitute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible	
DAW / May Not Substitut Prescriber's Signa		Date:	Prescriber's Signature:	Date:
- 1000or o orgina	ange is mandated unless Prescriber writes		ATTN: New York and lowa providers. pleas	

Pulmonary Arterial Hypertension (PAH) Infused/Inhaled Enrollment Form

Treprostinil (Generic Remodulin), Veletri, Epoprostenol (Generic Veletri)

ationt Name:		plete Patient and Prescriber Information			
atient Name: Patient DOB: rescriber Name: Prescriber Phone:					
	INFORMATION	Trescriber Friorie.			
IFUSED THERAPIE					
MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS		
Treprostinil Generic Remodulin)	1 mg/mL, 20 mL vial 2.5 mg/mL, 20 mL vial 5 mg/mL, 20 mL vial 10 mg/mL, 20 mL vial	□ IV infusion continuous over 24 hours □ Initial dose: ng/kg/min. Titrate by ng every days until goal of ng/kg/min ach Diluent: Check one (Sterile diluent for Treprostinil will k no box is checked) □ 0.9% NaCl for injection Sterile Water for Epoprostenol Sterile diluent Sterile diluent for Treprostinil Pump: 2 CADD-Legacy Pumps CVC Care: Dressing change every days Per IV standare.	onieved. Quantity: One-month supply of drug and supplies. Dosing weight: kg/lb Refills:		
☐ Veletri epoprostenol) for injection	☐ 0.5 mg vial ☐ 1.5 mg vial	IV infusion continuous over 24 hours Initial dose: ng/kg/min. Titrate by ng every days until goal of ng/kg/min ach Discharge dose: ng/kg/min Concentration: ng/mL Diluent: Check one (0.9% Sodium Chloride will be used box is checked) 0.9% NaCl for injection	g/kg/min nieved. Quantity: 30-day supply of drug and supplies. Dosing weight: kg/lb Refills:		
Epoprostenol Generic Veletri)		IV infusion continuous over 24 hours Initial dose: ng/kg/min. Titrate by ng every days until goal of ng/kg/min ach Discharge dose: ng/kg/min Concentration: ng/mL Diluent: Check one (0.9% Sodium Chloride will be used box is checked) □ 0.9% NaCl for injection □ Sterile Water for i Pump: 2 CADD-Legacy Pumps CVC Care: □ Dressing change every days. □ Per IV standar SIGNATURE NOT ALLOWED Ancillary supplies and kits p	g/kg/min nieved. Quantity: 30-day supply of drug and supplies. Dosing weight: kg/lb Refills: rd of care		
6	PRESCRIBER SIGNATU	RE REQUIRED (STAMP SIGNATURE NOT ALI	LOWED)		
•	Brand Medically Necessary / Do Not Subs				
Prescriber's Signature:		Date: Prescriber's Signature:	Date:		

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates. ©2022 CVS Specialty and/or one of its affiliates. 75-41534A 03/28/22 Page 3 of 3